|
Post by agedhippie on Apr 18, 2019 8:26:23 GMT -5
Epi pens are inexpensive? That's not what Matt said. What he said was " TreT is a good example of a drug where the increase in therapeutic benefit may outweigh the additional cost of production, epinephrine is not." Epi pens are expensive, but that says nothing about the cost of production and EpiPen's price hikes are a good example of that, actually insulin is a good example of that.
|
|
|
Post by liane on Apr 18, 2019 8:30:11 GMT -5
Is there an ignore feature on proboard. I want to make that my next move. Click "Help" at the top of the board; then Profile Privacy.
|
|
|
Post by buyitonsale on Apr 18, 2019 8:33:43 GMT -5
Afrezza lowers A1C under 7 without the risk of severe hypo. That’s not an incremental benefit. It’s s game changer.
If Q3 19 prints $9.7M net revenue, then EVER will most likely become achievable in Q4 20 - 18 months away.
|
|
|
Post by hellodolly on Apr 18, 2019 8:33:57 GMT -5
This board has debated at length the potential causes for the slow Rx growth, with insurance, marketing and uninformed doctors as the lead talking points. Afrezza may simply rest in what is described in the business literature as "The No Profit Zone"; there are lots of examples across all industries. Afrezza has its charms, no doubt, but it comes at a very high price relative to other options and managed care companies do not seem inclined to pay up for the additional value-added features, and physicians do not seem to convinced enough in the incremental benefits of Afrezza to fight the battle either. Afrezza has a high manufacturing cost relative to competitors, and even at higher production volume the cost disparity will remain, and the competition has started to retreat on recent price increases in face of public and Congressional criticism. When entrenched competitors have an absolute cost advantage and are rolling back pricing to earlier levels, the opportunity to ever make money on Afrezza may well be unachievable. That leaves the pipeline. Any drug that comes out of the pipeline effort will have the same manufacturing cost disadvantage as Afrezza, but inhaled delivery is a bigger deal for some drugs than for others. If MNKD carefully targets indications where inhalation provides a significant therapeutic advantage, there might be a workable strategy to turn the company around. If MNKD pursues formulations for any generic medication without regard to the increase in therapeutic benefit, they will likely not be successful. TreT is a good example of a drug where the increase in therapeutic benefit may outweigh the additional cost of production, epinephrine is not. Your point on 'cost' is simply adding more points to my closing statement. "... causes for the slow Rx growth, with insurance, marketing and uninformed doctors and costs..." Still has nothing to do with millennial PWDs being users or non-users. Just no way to quantify that subset. But, thanks for adding to the discussion.
|
|
|
Post by Clement on Apr 18, 2019 8:40:00 GMT -5
Previous speculation on this board suggested that Epi-Cricket might not have a superior therapeutic benefit, but a person hesistant to "spend" an epi pen could go ahead and use Epi-Cricket before it's too late. Therefore, an Epi-Cricket might be very desirable to have in a kit bag with epi pen. This scenario only works out if Epi-Cricket at scale could be produced at a low price. And Mike said we should not go it alone on this one.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 18, 2019 8:58:07 GMT -5
Previous speculation on this board suggested that Epi-Cricket might not have a superior therapeutic benefit, but a person hesistant to "spend" an epi pen could go ahead and use Epi-Cricket before it's too late. Therefore, an Epi-Cricket might be very desirable to have in a kit bag with epi pen. This scenario only works out if Epi-Cricket at scale could be produced at a low price. And Mike said we should not go it alone on this one. Epi-Cricket will have a great market segment. There's a 20 minute window before there's a severe reaction which the Cricket is perfect. I'm sure parents and patients would rather inhale than to JAB a needle into their thigh before they lose consciousness.
|
|
|
Post by brotherm1 on Apr 18, 2019 9:04:03 GMT -5
I’m sure also. I’m surprised we have not already found a partner for this. I feel we soon will though.
|
|
|
Post by sellhighdrinklow on Apr 18, 2019 9:05:23 GMT -5
.......or simply get an effective marketing campaign to pull patients into use. Afrezza is the real deal but Mannkind hasn't a clue on how to do an awesome marketing campaign. Maybe MC isn't the right guy if he can't get that going. So far he's just wasting money on ads that don't get noticed.
1000% agree.... what gives??? Marketing gets an F- in pay scale.
Maybe diabetics are asking their doctors about starting Affezza and their doctor says, "not for you" because the doctors are incompetent.
|
|
|
Post by liane on Apr 18, 2019 9:11:35 GMT -5
|
|
|
Post by mannmade on Apr 18, 2019 9:12:33 GMT -5
Previous speculation on this board suggested that Epi-Cricket might not have a superior therapeutic benefit, but a person hesistant to "spend" an epi pen could go ahead and use Epi-Cricket before it's too late. Therefore, an Epi-Cricket might be very desirable to have in a kit bag with epi pen. This scenario only works out if Epi-Cricket at scale could be produced at a low price. And Mike said we should not go it alone on this one. Epi-Cricket will have a great market segment. There's a 20 minute window before there's a severe reaction which the Cricket is perfect. I'm sure parents and patients would rather inhale than to JAB a needle into their thigh before they lose consciousness. And for people who are prone to stuations where they need epi having it on a key chain would be very convenient.
|
|
|
Post by mannmade on Apr 18, 2019 9:18:15 GMT -5
Honestly I think most doctors have the following issues:
1. Not enough time to educate themselves 2. A long history of teachings that insulin can kill if not administered correctly 3. They follow an SOC that says an Hba1c around 7 is good 4. They are not aware of Afrezza or do not know enough about it (follow up to item 1) 5. Afrezza is not from one of the big well known pharmas 6. Afrezza's label makes it look very similar to others 7. They do not have the time to fight insurance 8. There are a whole lot of other products that work for T2's and are less expensive 9. Dont have the time or staff to properly educate patients on Afrezza
When doctors start to reccomend Afrezza mnkd will have a blockbuster drug. This should happen over time. How long? I dont know...
Its a lot for mnkd to overcome but not impossible. Personally I would focus on organizations and institutions where I could find clusters of docs etc and also on global opinion leaders as well as finding rcognized diabetics as spokespersons. But that's just my two cents. They can do this...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 18, 2019 9:25:56 GMT -5
Honestly I think most doctors have the following issues: 1. Not enough time to educate themselves 2. A long history of teachings that insulin can kill if not administered correctly 3. They follow an SOC that says an Hba1c around 7 is good 4. They are not aware of Afrezza or do not know enough about it (follow up to item 1) 5. Afrezza is not from one of the big well known pharmas 6. Afrezza's label makes it look very similar to others 7. They do not have the time to fight insurance 8. There are a whole lot of other products that work for T2's and are less expensive 9. Dont have the time or staff to properly educate patients on Afrezza When doctors start to reccoment Afrezza mnkd will have a blockbuster drug. This should happen oer time. How long? I dont know... Its a lot for mnkd to overcome but not impossible. Personally I would focus on organizations and institutions where I could find clusters of docs etc and also on global opinion leaders as well as finding rcognized diabetics as spokespersons. But tht just my two cents. They can do this... Excellent summation. What's good is that your summary is the NORM for most NEW DRUGS and THERAPIES.
|
|
|
Post by agedhippie on Apr 18, 2019 9:30:00 GMT -5
Previous speculation on this board suggested that Epi-Cricket might not have a superior therapeutic benefit, but a person hesistant to "spend" an epi pen could go ahead and use Epi-Cricket before it's too late. Therefore, an Epi-Cricket might be very desirable to have in a kit bag with epi pen. This scenario only works out if Epi-Cricket at scale could be produced at a low price. And Mike said we should not go it alone on this one. What I am looking for is a pipeline of customers like RLS and UTHR wanting their product packed for inhalation. I see minimal value in the independent efforts because, like Epihale, there is not the cash to get these past the proof of concept stage. In the past these served the purpose of showcasing what could be done, but now UTHR provides far more credibility.
|
|
|
Post by mannmade on Apr 18, 2019 9:37:09 GMT -5
Previous speculation on this board suggested that Epi-Cricket might not have a superior therapeutic benefit, but a person hesistant to "spend" an epi pen could go ahead and use Epi-Cricket before it's too late. Therefore, an Epi-Cricket might be very desirable to have in a kit bag with epi pen. This scenario only works out if Epi-Cricket at scale could be produced at a low price. And Mike said we should not go it alone on this one. What I am looking for is a pipeline of customers like RLS and UTHR wanting their product packed for inhalation. I see minimal value in the independent efforts because, like Epihale, there is not the cash to get these past the proof of concept stage. In the past these served the purpose of showcasing what could be done, but now UTHR provides far more credibility. Yes I think mnkd's success will wind up being the collective value of its portfolio whether or not Afrezza is the big revenue driver, collectively the revenue should eventually lead to continued share appreciation well beyond today's current value and if they can continue to add to the portfolio it could go on for years to come.
|
|
painter
Newbie
Adcirca = Tadalifil = Cialis = Very large market. Please correct me if inaccurate.
Posts: 3
|
Post by painter on Apr 18, 2019 10:16:03 GMT -5
Mike: Go back to basics. Don't sell to attributes. Sell to needs. Your syringe print advertisement shows real potential. But, what value does saying "after 97 years". Your ad should empower and give direction. Consider the following: after the syringe lineup why not just print "or" and then show someone perhaps middle age using the dreamboat inhaler. Follow that up with "you have a choice" Mankind etc. Stories sell. You have wasted investors money with your long running cable adverts. You have done focus groups. Directly and visually convey problems and solutions. Innovators willing to experiment usually represent 4-5% market share. I believe 14-18% to arrive at a tipping point. Focus on one or two major markets. (Imagine setting up a booth in Grand Central Station. Only kidding.) New York is replete with street fairs during spring and summer months.
|
|